Filing Details

Accession Number:
0001213900-25-015019
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-02-18 21:54:19
Reporting Period:
2025-02-18
Filing Date:
2025-02-18
Accepted Time:
2025-02-18 21:54:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
2028614 Drugs Made In America Acquisition Corp. DMAA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1927032 Lynn Stockwell C/O Drugs Made In America Acq. Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale FL 33301
Ceo And Exe. Chair Of Board Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2025-02-18 30,000 $0.00 4,188,780 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Rights to receive ordinary shares Acquisiton 2025-02-18 30,000 $0.00 30,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
430,000 No 4 P Indirect
Footnotes
  1. Reflects the 30,000 private units acquired by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
  2. The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.